VivoSeq
Other

PIK3CA Mutation

4

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

PIK3CA Mutation is an early-stage landscape with 4 programs across 4 companies. The most active players are Cogent Biosciences, Inc., Relay Therapeutics, AstraZeneca. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cogent Biosciences, Inc.

1 program

Phase 1Relay Therapeutics logo

Relay Therapeutics

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3F

Fresenius Kabi Oncology Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05490771·35 enrolled
A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor
Recruiting·Relay Therapeutics logoRelay Therapeutics·Phase 3·NCT06982521·540 enrolled
A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
Recruiting·CCogent Biosciences, Inc.·Phase 1·NCT07383506·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)